XML 126 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)
12 Months Ended
Dec. 31, 2019
USD ($)
Japan [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Remainder of transaction price, variable consideration from estimated future co-development billing $ 0
Japan [Member] | Astellas Agreement [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue due to prior period adjustment of performance obligations 12,100,000
Europe [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Remainder of transaction price, variable consideration from estimated future co-development billing 45,400,000
Europe [Member] | Astellas Agreement [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue due to prior period adjustment of performance obligations 124,700,000
U.S./RoW and China [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Remainder of transaction price, variable consideration from estimated future co-development billing 130,400,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue due to prior period adjustment of performance obligations $ 62,600,000